ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Shannon Entropy of Gray Matter Eigenmodes: A Novel Biomarker for Alzheimer's Disease and Heterogeneous MCI Trajectories.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shannon Entropy of Gray Matter Eigenmodes: A Novel Biomarker for Alzheimer's Disease and Heterogeneous MCI Trajectories.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Current Alzheimer's disease (AD) diagnostics rely on late-stage cognitive assessments or invasive biomarkers. Neuroimaging offers non-invasive alternatives, but single-modality approaches (structural atrophy or functional connectivity) face limitations in sensitivity and specificity for early detection. Entropy and temperature, novel structure-function coupling (SFC) biomarkers based on gray matter eigenmodes, are introduced to quantify cortical disorganization in early AD. Using multimodal MRI and amyloid-PET data from two cohorts (BABRI: N = 135; ADNI: N = 275), including cognitively normal (CN), mild cognitive impairment (MCI), and AD individuals, entropy is computed by projecting fMRI onto structural eigenmodes and temperature via eigenmode-based functional connectivity reconstruction. These indices are tested for diagnostic classification, Aβ prediction, and MCI subtype stratification (reversed/stable/progressed). Entropy is significantly higher in AD than CN and MCI (Δ = 8-21%, p < 0.001) in both cohorts. Left-hemisphere entropy yielded optimal diagnostic accuracy (AUC = 0.901 for CN vs MCI), while right/global entropy predicted Aβ burden (error reduction: 38.7-42.1%, p < 0.01). Entropy also distinguished MCI subtypes and captured biphasic changes in progressors. Temperature indices showed no significant group differences. Entropy from gray matter eigenmodes is a sensitive, non-invasive biomarker for AD diagnosis and pathology prediction, revealing hemispheric asymmetries and nonlinear progression in MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.